Global interest in Rosemont grows

The Leeds company develops, manufactures and supplies liquid medicines for patients who have difficulty in swallowing tablets and capsules.

It is highly profitable and made a pre-tax profit of £14.63m on turnover of £35.81m in 2011. CBPE, the private equity house, paid just under £100m for Rosemont in 2006 and asked corporate financiers at Rothschild to find a new own- er.

Trade buyers in America, Europe and the Far East have expressed an interest, as have buyout firms in Britain and Eur- ope.

The sale is likely to be completed during the next six weeks.

Rosemont invests heavily in research and development – £3.33m last year – to expand its product portfolio to keep it ahead of generic competition in the UK pharmaceuticals market.

Rosemont’s main market is the UK, but the firm is pursuing opportunities overseas in the US and Europe.